Pattern Bioscience Raises $43 Million in Series D Financing to Pursue FDA Clearance for Its Rapid Pneumonia Diagnostic

Funding led by AMR Action Fund, Illumina Ventures, and Omnimed Capital supports U.S. clinical trial and 510(k) submission for rapid Pneumonia identification and antibiotic susceptibility testing (ID/AST) panel AUSTIN, Texas, November 18, 2025: Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, announced it has raised $43 million in Series D financing, led […] The post Pattern Bioscience Raises $43 Million in Series D Financing to Pursue FDA Clearance for Its Rapid Pneumonia Diagnostic appeared first on Pattern Bioscience .